132 related articles for article (PubMed ID: 19141860)
1. Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia.
Kim DH; Xu W; Ma C; Liu X; Siminovitch K; Messner HA; Lipton JH
Blood; 2009 Mar; 113(11):2517-25. PubMed ID: 19141860
[TBL] [Abstract][Full Text] [Related]
2. Single nucleotide polymorphism in PTEN-Long gene: A risk factor in chronic myeloid leukemia.
Ferri C; Weich N; Gutiérrez L; De Brasi C; Bengió MR; Zapata P; Fundia A; Larripa I
Gene; 2019 Apr; 694():71-75. PubMed ID: 30738963
[TBL] [Abstract][Full Text] [Related]
3. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.
Chen Y; Fang F; Hu Y; Liu Q; Bu D; Tan M; Wu L; Zhu P
PLoS One; 2016; 11(4):e0154183. PubMed ID: 27111338
[TBL] [Abstract][Full Text] [Related]
4. Chronic Myeloid Leukemia (CML) Mouse Model in Translational Research.
Peng C; Li S
Methods Mol Biol; 2016; 1438():225-43. PubMed ID: 27150093
[TBL] [Abstract][Full Text] [Related]
5. Association of Vascular Endothelial Growth Factor A (VEGFA) and its Receptor (VEGFR2) Gene Polymorphisms with Risk of Chronic Myeloid Leukemia and Influence on Clinical Outcome.
Lakkireddy S; Aula S; Kapley A; Swamy AV; Digumarti RR; Kutala VK; Jamil K
Mol Diagn Ther; 2016 Feb; 20(1):33-44. PubMed ID: 26476544
[TBL] [Abstract][Full Text] [Related]
6. Association of promoter polymorphisms of Fas -FasL genes with development of Chronic Myeloid Leukemia.
Edathara PM; Gorre M; Kagita S; Vuree S; Cingeetham A; Nanchari SR; Meka PB; Annamaneni S; Digumarthi RR; Satti V
Tumour Biol; 2016 Apr; 37(4):5475-84. PubMed ID: 26563376
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms associated with increased risk of developing chronic myelogenous leukemia.
Bruzzoni-Giovanelli H; González JR; Sigaux F; Villoutreix BO; Cayuela JM; Guilhot J; Preudhomme C; Guilhot F; Poyet JL; Rousselot P
Oncotarget; 2015 Nov; 6(34):36269-77. PubMed ID: 26474455
[TBL] [Abstract][Full Text] [Related]
8. [Association of CD38 gene polymorphism with pathogenesis of chronic myeloid leukemia].
Li J; Zhu JF; Zhang W; Ma HZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):284-7. PubMed ID: 21518472
[TBL] [Abstract][Full Text] [Related]
9. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
10. The rs61764370 Functional Variant in the KRAS Oncogene is Associated with Chronic Myeloid Leukemia Risk in Women.
Gutiérrez-Malacatt H; Ayala-Sanchez M; Aquino-Ortega X; Dominguez-Rodriguez J; Martinez-Tovar A; Olarte-Carrillo I; Martinez-Hernandez A; C CC; Orozco L; Cordova EJ
Asian Pac J Cancer Prev; 2016; 17(4):2265-70. PubMed ID: 27221928
[TBL] [Abstract][Full Text] [Related]
11. Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia.
Zheng Q; Cao J; Hamad N; Kim HJ; Moon JH; Sohn SK; Jung CW; Lipton JH; Kim DD
J Transl Med; 2016 Mar; 14():82. PubMed ID: 27009330
[TBL] [Abstract][Full Text] [Related]
12. Expression of Hippo signaling pathway and Aurora kinase genes in chronic myeloid leukemia.
Marsola APZC; Simões BP; Palma LC; Berzoti-Coelho MG; Burin SM; de Castro FA
Med Oncol; 2018 Jan; 35(3):26. PubMed ID: 29387948
[TBL] [Abstract][Full Text] [Related]
13. Expression differences of genes in the PI3K/AKT, WNT/b-catenin, SHH, NOTCH and MAPK signaling pathways in CD34+ hematopoietic cells obtained from chronic phase patients with chronic myeloid leukemia and from healthy controls.
de Cássia Viu Carrara R; Fontes AM; Abraham KJ; Orellana MD; Haddad SK; Palma PVB; Panepucci RA; Zago MA; Covas DT
Clin Transl Oncol; 2018 Apr; 20(4):542-549. PubMed ID: 28905209
[TBL] [Abstract][Full Text] [Related]
14. hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia.
Ben Hassine I; Gharbi H; Soltani I; Teber M; Farrah A; Ben Hadj Othman H; Amouri H; Bellaaj H; Lakhal RB; Romdhane NB; Abbes S; Menif S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):737-745. PubMed ID: 28286932
[TBL] [Abstract][Full Text] [Related]
15. Evidence that 6q25.1 variant rs6931104 confers susceptibility to chronic myeloid leukemia through RMND1 regulation.
Woo YM; Kim S; Park JH; Lee NY; Kim JW; Kim DDH
PLoS One; 2019; 14(6):e0218968. PubMed ID: 31237926
[TBL] [Abstract][Full Text] [Related]
16. Single nucleotide polymorphisms of multidrug resistance gene 1 (MDR1) and risk of chronic myeloid leukemia.
Yaya K; Hind D; Meryem Q; Asma Q; Said B; Sellama N
Tumour Biol; 2014 Nov; 35(11):10969-75. PubMed ID: 25087925
[TBL] [Abstract][Full Text] [Related]
17. The genetic polymorphism and expression profiles of NLRP3 inflammasome in patients with chronic myeloid leukemia.
Zhang A; Yu J; Yan S; Zhao X; Chen C; Zhou Y; Zhao X; Hua M; Wang R; Zhang C; Zhong C; He N; Ji C; Ma D
Hum Immunol; 2018 Jan; 79(1):57-62. PubMed ID: 29097263
[TBL] [Abstract][Full Text] [Related]
18. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
[TBL] [Abstract][Full Text] [Related]
19. HLA system affects the age-at-onset in chronic myeloid leukemia.
Oguz FS; Kalayoglu S; Diler AS; Tozkir H; Sargin D; Carin M; Dorak MT
Am J Hematol; 2003 Aug; 73(4):256-62. PubMed ID: 12879429
[TBL] [Abstract][Full Text] [Related]
20. [Variation of LNK Gene in Chronic Myeloid Leukemia].
Tan M; Rong Y; Tian RM; Zhu YH; Zhu P; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):706-710. PubMed ID: 28641622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
